Evidence map›Paper›PMID 42309024›Full record

Observational studyBreast (Edinburgh, Scotland)2026

De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study.

Tal Sella, Frederieke van Duijnhoven, Hans Wildiers, Claudio Venieri, Katarzyna Pogoda, Barbro Linderholm, Leonor Matos, Natali Shirron, Eleonora De Maio D'Esposito, Nawale Hajjaji and 23 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Tal SellaDepartment of Oncology, Chaim Sheba Medical Center, Tel HaShomer, Israel.
Frederieke van DuijnhovenDepartment of Surgical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
Hans WildiersDepartment of General Medical Oncology and Multidisciplinary Breast Center, University Hospitals Leuven, Leuven, Belgium.
Claudio VenieriDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
Katarzyna PogodaMaria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Barbro LinderholmInstitute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy at Gothenburg University and Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Leonor MatosBreast Unit, Champalimaud Clinical Center, Lisbon, Portugal.
Natali ShirronOncology Wing, RAMBAM Health Care Campus, Haifa, Israel.
Eleonora De Maio D'EspositoInstitut Universitaire du Cancer Toulouse - Oncopole, France.
Nawale HajjajiCentre Oscar Lambret, Lille, France.
Erika MatosInstitute of Oncology Ljubljana, Slovenia.
Lucía González CortijoHospital Universitario Quirónsalud, Madrid, Spain.
Matteo LambertiniDepartment of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Azienda Ospedaliera Metropolitana, Genova, Italy; Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genova, Italy.
Ana FortunaUnidade Local de Saúde do Algarve, Portugal.
Laurent RossetCentre du sein Fribourg, Switzerland.
Anastasia ConstantinidouBank of Cyprus Oncology Centre, Medical School University of Cyprus, Nicosia, Cyprus.
Sofie DemasureAZ Groeninge vzw, Campus kennedylaan, Kortrijk, Belgium.
Areen Abu RemilahDepartment of Oncology, Shaare Zedek Medical Center, Jerusalem, Israel.
Greet HuyghAZORG, Campus Moorselbaan, Belgium.
Shani Paluch-ShimonSharett Institute of Oncology, Hadassah University Hospital, Israel; Faculty of Medicine Hebrew University, Jerusalem, Israel.
Vivianne Tjan-HeijnenDiv. Medical Oncology, Maastricht UMC+, Maastricht, Netherlands.
Natacha RuyssersDept of Surgical Oncology, AZ Turnhout, Belgium.
Helena GouveiaBreast Unit, Champalimaud Clinical Center, Lisbon, Portugal.
Eurydice AngeliDepartment of Medical Oncology, Hôpital Avicenne, Bobigny, France.
Irfan CicinDepartment of Medical Oncology, Istinye University, Istanbul, Turkey.
Edoardo ChiappeDepartment of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Azienda Ospedaliera Metropolitana, Genova, Italy; Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genova, Italy.
Patrick NevenDepartment of General Medical Oncology and Multidisciplinary Breast Center, University Hospitals Leuven, Leuven, Belgium.
Mehmet ArtacNecmettin Erbakan University, Department of Medical Oncology, Konya, Turkey.
Bilgesah KilictasNecmettin Erbakan University, Department of Medical Oncology, Konya, Turkey.
Jalal BaransehOncology Wing, RAMBAM Health Care Campus, Haifa, Israel.
Elena Vicente-RubioCanarian Comprehensive Cancer Center, San Roque University Hospital, Las Palmas de Gran Canaria, Spain.
Mustafa AtciDepartment of Medical Oncology, Istinye University, Istanbul, Turkey.
Ayelet ShaiOncology Wing, RAMBAM Health Care Campus, Haifa, Israel; Technion Israel Institute of Technology, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel. Electronic address: a_shai@rmc.gov.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUse of taxane-only chemotherapy for stage I HR+/HER2+ breast cancer has increased, potentially preserving ovarian function and shifting endocrine therapy (ET) strategies. Outcomes in premenopausal women were not defined.

methodsPatients ≤45 years with stage I HR+/HER2+ breast cancer were identified from a multicenter registry. IDFS was assessed by chemotherapy and ET.

resultsThirteen IDFS events (4 distant) occurred among 244 patients. Six-year IDFS was 95.5% (multiagent chemotherapy) and 94.1% (taxane-only) (p = 0.56), and 95.9%, 93.8%, and 96.9% with tamoxifen, tamoxifen + OFS, and AI + OFS (p = 0.56).

conclusionsOutcomes were excellent regardless of chemotherapy or ET, suggesting limited incremental benefit from treatment intensification.

Indexed as

Antineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsAdultAromatase InhibitorsChemotherapy, AdjuvantDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesFemaleHumansNeoplasm StagingPremenopauseReceptors, EstrogenReceptors, ProgesteroneRegistriesTamoxifenAntineoplastic Agents, HormonalAromatase InhibitorsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneTamoxifenTaxoidsChemotherapyEndocrine therapyHER2-PositivePremenopausalStage I

Identifiers

PMID42309024
PMCPMC13311277

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.